Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Bevacizumab with Chemotherapy in Advanced Pancreatic Cancer
NCT07235930Phase 3Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2025
- Primary completion
- Jul 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of serplulimab, bevacizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang Cancer Hospital. Started Nov 2025; status: recruiting.
02
Drugs
serplulimabbevacizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07235930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07235930.